Protecting Our Pharmaceutical Supply Chain from China Act of 2020

Bill: 116-s-3635
Sponsor: full_name: Sen. Cotton, Tom [R-AR]
Introduced: 2020-05-06
Policy area: Health
Subjects: Asia

Business expenses

China

Drug safety, medical device, and laboratory regulation

Government information and archives

Health care costs and insurance

Health programs administration and funding

Health technology, devices, supplies

Income tax deductions

Manufacturing

Military medicine

Military procurement, research, weapons development

Prescription drugs

Public contracts and procurement

Trade restrictions

Veterans' medical care
Latest action: action_date: 2020-05-06
text: Read twice and referred to the Committee on Finance.

Summaries:
action_date: 2020-05-06
action_desc: Introduced in Senate
text: <p><strong>Protecting Our Pharmaceutical Supply Chain from China Act of 2020</strong></p> <p>This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.</p>

tv_txt: II 116th CONGRESS 2d Session S. 3635 IN THE SENATE OF THE UNITED STATES May 6, 2020 Mr. Cotton (for himself, Mrs. Blackburn , Mr. Cruz , Mr. Daines , and Mr. Scott of Florida ) introduced the following bill; which was read twice and referred to the Committee on Finance A BILL To require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of, or reimbursement for, drugs manufactured in China, and for other purposes.

1. Short title This Act may be cited as the Protecting Our Pharmaceutical Supply Chain from China Act of 2020 . 2. Country of origin of drugs (a) In general Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq.) is amended by adding at the end the following: 524B. Registry of drugs produced outside the United States (a) In general The Secretary shall compile and maintain a list of all drugs approved under subsection (c) or (j) of section 505 of this Act or licensed under subsection (a) or (k) of section 351 of the Public Health Service Act, and any active ingredients in such drugs, that— (1) are manufactured outside of the United States; and (2) are determined by the Secretary to be critical to the health and safety of consumers in the United States. (b) Additional list In conjunction with the list described in subsection (a), the Secretary shall compile and maintain a list of drugs included on such list that are exclusively produced in, or use active or inactive ingredients produced in, the People's Republic of China. (c) Requirement The list described in subsection (a) shall, with respect to each drug included on the list, provide information about the drug’s supply chain, including each step in the supply chain that occurs prior to the drug’s importation into the United States. . (b) Federal health program purchase of, or reimbursement for, drugs (1) In general Notwithstanding any other provision of law, the Department of Health and Human Services, the Department of Veterans Affairs, the Department of Defense, and any other Federal health care program (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320a–7b(b)), with respect to the purchase of, or reimbursement for, a drug by such agency or program, the following shall apply: (A) By 2022, a purchaser of, or reimbursor for, drugs described in this subsection shall purchase drugs or reimburse for drugs only if such drugs contain 60 percent or more of their active pharmaceutical ingredients manufactured in countries— (i) other than the People’s Republic of China; and (ii) that meet the Food and Drug Administration’s health and safety standards. (B) By 2023, a purchaser of, or reimbursor for, drugs described in this subsection shall purchase drugs or reimburse for drugs only if such drugs contain 100 percent of their active pharmaceutical ingredients manufactured in countries— (i) other than the People’s Republic of China; and (ii) that meet the Food and Drug Administration’s health and safety standards. (2) Waivers The Secretary of Health and Human Services may issue waivers of the requirements under paragraph (1) for any agency or program that is unable to meet such requirements and demonstrates a need for the waiver. No waiver may be issued under this paragraph for drugs that are purchased on or after January 1, 2025. (c) Labeling requirement Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following: (ee) If it is a drug and its labeling does not specify the country of origin of each active ingredient contained in the drug. . 3. Temporary 100 percent expensing for pharmaceutical and medical device manufacturing property (a) In general For purposes of section 168(k) of the Internal Revenue Code of 1986, in the case of any qualified pharmaceutical and medical device manufacturing property which is placed in service after December 31, 2019, and before January 1, 2026— (1) such property shall be treated as qualified property (within the meaning of such section), (2) the applicable percentage otherwise determined under section 168(k)(6) of such Code with respect to such property shall be 100 percent, and (3) paragraph (8) of such section shall not apply. (b) Qualified pharmaceutical and medical device manufacturing property For purposes of this section, the term qualified pharmaceutical and medical device manufacturing property means any tangible property placed in service in the United States as part of the construction or expansion of property for the manufacture of drugs (as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(g) )) or medical devices (as defined in section 201(h) of such Act ( 21 U.S.C. 321(h) )). (c) Termination This section shall not apply to any property placed in service after December 31, 2025. 4. Rule of construction Nothing in this Act shall be construed to divert the resources of the Food and Drug Administration from responding to the COVID–19 public health emergency.